Drug Screening in Experimental and Clinical Studies Targeting the Blood Brain Barrier
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: closed (15 October 2021) | Viewed by 13039
Special Issue Editor
Interests: blood brain barrier; neurodegenerative disorders; neuroinflammation; electrophysiology; calcium signaling; pharmacology; drug screening
Special Issue Information
Dear Colleagues,
Blood brain barrier (BBB) is a key regulator for the access of any drug to the brain parenchyma. There are multiple transport systems in the BBB including ion channels, membrane transport of small lipophilic substances, carrier-mediated transport, receptor-mediated transport, adsorption-mediated transcytosis transport, active efflux transporters etc. Various drugs may either directly affect the transport through these systems, or indirectly regulate their gene/protein expression, thus contributing to their up/downregulation and internalization mechanisms, that finally affects the expected drug transport across the BBB. For this reason, accurate information regarding the interaction with drugs or their permeability through the BBB is necessary, making drug screening and drug safety assays mandatory for any commercial or newly synthesized drug. Moreover, the mechanisms behind BBB alterations in various pathologies must be understood to ensure the optimal drug delivery. To this purpose, experimental in silico, in vitro, and in vivo studies have brought essential information for drug development. Additionally, several strategies have been developed to increase the efficiency of drug delivery to brain parenchyma, especially in clinical situations (i.e. neuro-oncology, pharmacoresistance), where BBB transport mechanisms are altered due to the pathological condition.
For this Special Issue of Biomolecules, “’Drug screening in experimental and clinical studies targeting the blood brain barrier”, we encourage the submission of primary research and review articles that are focused on the transport and mechanism of action for commercial and newly-synthesized drugs at the BBB level, either in preclinical or clinical studies.
Dr. Beatrice Mihaela Radu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Blood Brain Barrier
- In silico models
- In vitro models
- In vivo models
- Clinical studies
- Drug screening
- Drug safety
- Pharmacology
- Pharmacoresistance
- Central nervous systems disorders